US2017342089A1PendingUtilityA1

Novel compounds as modulators of gpr-119

54
Assignee: RHIZEN PHARMACEUTICALS SAPriority: Jun 9, 2011Filed: Aug 10, 2017Published: Nov 30, 2017
Est. expiryJun 9, 2031(~4.9 yrs left)· nominal 20-yr term from priority
A61P 9/12A61P 3/06A61P 5/48A61P 43/00A61P 3/10A61P 9/04A61P 9/10A61P 9/00A61P 25/16A61P 27/02A61P 27/06A61P 25/08A61P 3/00A61P 25/02A61P 3/04A61P 25/14A61P 29/00A61P 27/12A61P 25/28A61P 1/18A61P 25/00A61P 19/08A61P 17/02A61P 1/00A61P 13/12C07D 405/04C07D 417/14C07D 417/04C07D 401/14C07D 413/04C07D 401/04C07D 413/14C07D 498/04A61K 31/4535A61K 31/4525C07D 403/14
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.

Claims

exact text as granted — not AI-modified
1 - 33 . (canceled) 
     
     
         34 . A compound of formula (A-I), (A-II), (B-I), (B-II), (B-III) and (B-IV): 
       
         
           
           
               
               
           
         
       
       or a tautomer, stereoisomer, enantiomer, diastereomer, salt, or N-oxide thereof, 
       wherein
 Ar is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or Cy 1 ; 
 X 1  is CR 1  or N; X 2  is CR 2  or N; X 3  is CR 3  or N; and X 4  is CR 4  or N; 
 X is CR or N; 
 Z is NR; 
 Cy 1  is selected from substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocyclic group; 
 each occurrence of R, R 2 , and R 3  may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, substituted or unsubstituted C 3-6  cycloalkenyl, —OR a , —S(═O) q —R a , —NR a R b , C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b —, —C(═Y)—NR a R b —, —NR a —C(═Y)—NR a R b —, —S(═O) q —NR a R b —, —NR a —S(═O) q —NR a R b —, and —NR a —NR a R b —; 
 each occurrence of R 1  and R 4  may be same or different and is independently selected from hydrogen, nitro, hydroxy, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, substituted or unsubstituted C 3-6  cycloalkenyl, —OR a , —S(═O) q —R a , —NR a R b , C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b —, —C(═Y)—NR a R b —, —NR a —C(═Y)—NR a R b —, —S(═O) q —NR a R b —, —NR a —S(═O) q —NR a R b —, and —NR a —NR a R b ; 
 each occurrence of R a  and R b  may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl, or when two R a  and/or R b  substituents are directly bound to a common atom, they may be joined to form (i) an oxo (═O), thio (═S) or imino (═NR d ), or (ii) a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c  or S; 
 each occurrence of R c  is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl; 
 each occurrence of Y is independently selected from O, S, and NR a ; and 
 each occurrence of q independently represents 0, 1 or 2; 
 D and E are independently selected from CH or N; 
 R 5  is selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —COOR a , —C(O)R a , —C(S)R a , —C(O)NR a R b , —C(O)ONR a R b , —NR a R b , —NR a CONR a R b , —N(R a )SOR b , —N(R a )SO 2 R b , -(═N—N(R a )R b ), —NR a C(O)OR b , —NR a C(O)R b —, —NR a C(S)R b  NR a C(S)NR a R b , —SONR a R b —, —OR a , —OR a C(O)NR a R b , —OR a C(O)OR b —, —OC(O)R a , —OC(O)NR a R b , —R a NR b C(O)R a , —R a OR b , —R a C(O)OR b , —R a C(O)NR a R b , —R a C(O)R b , —R a OC(O)R b , —SR a , —SOR a , —SO 2 R a , and —ONO 2 ; with the proviso that when R 5  is —SO 2 R a , then R a  is not unsubstituted alkyl; 
 each occurrence of R d  is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocycicyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and —ONO 2 , or any two of R d  which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR′ (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR′); and 
 each occurrence of R e , R f , R g , R h , R i , R j , R k  and R l  is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl; or any two of R e , R f , R g , R h , R i , R j , R k , and R l  may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR′ (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR′) (where R′ is H or alkyl); and 
 each of r, s, t and u is 0, 1 or 2 with the proviso that r+s+t+u 0. 
 
     
     
         35 . A compound of formula (A-III) and (A-IV): 
       
         
           
           
               
               
           
         
       
       or a tautomer, stereoisomer, enantiomer, diastereomer, salt, or N-oxide thereof, 
       wherein
 Ar is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or Cy 1 ; 
 X 1  is CR 1  or N; X 2  is CR 2  or N; X 3  is CR 3  or N; and X 4  is CR 4  or N; 
 X is CR or N; 
 Z is NR; 
 Cy 1  is selected from substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocyclic group; 
 each occurrence of R, R 2 , and R 3  may be same or different and is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, substituted or unsubstituted C 3-6  cycloalkenyl, —OR a , —S(═O) q —R a , —NR a R b , C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b —, —C(═Y)—NR a R b —, —NR a —C(═Y)—NR a R b —, —S(═O) q —NR a R b —, —NR a —S(═O) q —NR a R b —, and —NR a —NR a R b —; 
 each occurrence of R 1  and R 4  may be same or different and is independently selected from hydrogen, nitro, hydroxy, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, substituted or unsubstituted C 3-6  cycloalkenyl, —OR a , —S(═O) q —R a , —NR a R b , C(═Y)—R a , —CR a R b —C(═Y)—R a , —CR a R b —Y—CR a R b —, —C(═Y)—NR a R b —, —NR a —C(═Y)—NR a R b —, —S(═O) q —NR a R b —, —NR a —S(═O) q —NR a R b —, and —NR a —NR a R b —; 
 each occurrence of R a  and R b  may be same or different and are independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl, or when two R a  and/or R b  substituents are directly bound to a common atom, they may be joined to form (i) an oxo (═O), thio (═S) or imino (═NR d ), or (ii) a substituted or unsubstituted, saturated or unsaturated 3-10 member ring, which may optionally include one or more heteroatoms which may be same or different and are selected from O, NR c  or S; 
 each occurrence of R c  is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl; 
 each occurrence of Y is independently selected from O, S, and NR a ; and 
 each occurrence of q independently represents 0, 1 or 2; 
 D and E are independently selected from CH or N; 
 R 5  is selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, —COOR a , —C(O)R a , —C(S)R a , —C(O)NR a R b , —C(O)ONR a R b , —NR a R b , —NR a CONR a R b , —N(R a )SOR b , —N(R a )SO 2 R b , -(═N—N(R a )R b ), —NR a C(O)OR b , —NR a C(O)R b —, —NR a C(S)R b  NR a C(S)NR a R b , —SONR a R b —, —SO 2 NR a R b —, —OR a , —OR a C(O)NR a R b , —OR a C(O)OR b —, —OC(O)R a , —OC(O)NR a R b , —R a NR b C(O)R a , —R a OR b , —R a C(O)OR b , —R a C(O)NR a R b , —R a C(O)R b , —R a OC(O)R b , —SR a , —SOR a —SO 2 R a , and —ONO 2 , 
 each occurrence of R d  is independently hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio (═S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclcyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, and —ONO 2 , or any two of R d  which are directly bound to a common atom may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR′ (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR′); and 
 each occurrence of R e , R f , R g , R h , R i , R j , R k  and R l  is independently selected from hydrogen, nitro, hydroxy, cyano, halogen, substituted or unsubstituted C 1-6  alkyl, substituted or unsubstituted C 2-6  alkenyl, substituted or unsubstituted C 2-6  alkynyl, substituted or unsubstituted C 3-6  cycloalkyl, substituted or unsubstituted C 3-6  cycloalkylalkyl, and substituted or unsubstituted C 3-6  cycloalkenyl; or any two of R e , R f , R g , R h , R i , R j , R k , and R 1  may be joined to form (i) a substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR′ (where R′ is H or alkyl) or S, or (ii) an oxo (═O), thio (═S) or imino (═NR′) (where R′ is H or alkyl); and 
 each of r, s, t and u is 0, 1 or 2 with the proviso that r+s+t+u≠0, 
 
     
     
         36 . A compound of  claim 34 , wherein Ar is selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         37 . A compound of  claim 34 , wherein Z is NH or N—CH 3 . 
     
     
         38 . A compound of  claim 34 , wherein Cy 1  is selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         39 . A compound of  claim 34 , wherein R 5  is selected from 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         40 . A compound of  claim 34 , wherein R 5  is —C(O)OC(CH 3 ) 3  or —C(O)OCH(CH 3 ) 2 . 
     
     
         41 . A compound selected from
 2-[1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl]-5-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-benzo[d]imidazole;   Tert-butyl 4-{5-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-benzo[d]imidazol-2-yl}piperidine-1-carboxylate;   Tert-butyl 4-{5-[2-fluoro-4-(methylsulfonyl)phenyl]-1-methyl-1H-benzo[d]imidazol-2-yl}piperidine-1-carboxylate;   Tert-butyl 4-{2-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-benzo[d]imidazol-5-yl}-5,6-dihydropyridine-1(2H)-carboxylate;   Tert-butyl 4-{2-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-benzo[d]imidazol-5-yl}piperidine-1-carboxylate;   5-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-2-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-benzo[d]imidazole;   
       and pharmaceutically acceptable salts thereof. 
     
     
         42 . A pharmaceutical composition comprising a compound of  claim 34  and a pharmaceutically acceptable carrier. 
     
     
         43 . The pharmaceutical composition of  claim 34 , further comprising one or more additional therapeutic agents and mixtures thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.